However, our results demonstrate that DARA-IgA2 is more efficient in activating PMN for T-ALL cell killing compared to the clinically available IgG1 antibody, especially in combination with CD47 blockade. This evidence concerns the gene CD47 and acute lymphoblastic leukemia.